$20.31 billion Founded in 1978 in Switzerland as one of the first biotech companies, Biogen today (NASDAQ:BIIB) discovers, develops, and sells therapies for neurological and neurodegenerative ...
Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...
Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...
Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...
Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.